Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study
{{output}}
Background: Patients treated with anti-CD20 monoclonal antibodies could have a higher risk of adverse outcomes of coronavirus disease 2019 (COVID-19). The novel anti-CD20 monoclonal antibody obinutuzumab has shown greater B-cell ... ...
